One of our favorite biotech stocks, Inovio Pharmaceuticals Inc. (Nasdaq: INO), has seen a steep fall lately. Inovio stock is down 20.5% since it reached a 2015 high of $10.77 on April 22. Even with this recent slip, INO is still one of our biggest triple-digit winners. Inovio stock is up 241% since Money Morning 's Executive Editor Bill Patalon first recommended it to his readers in February 2013. A 20% drop can send investors running for the exits. But now is not the time to panic and sell. Inovio stock remains a long-term stock to buy. Here's why... Tags: INO stock , INO stock price , Inovio , Inovio Stock , Inovio stock price , Nasdaq: INO To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Why Inovio Stock Is Still a Buy After a 20% Dip appeared first on Money Morning - We Make Investing Profitable .